On Friday, Galapagos ADR earned an upgrade to its Relative Strength (RS) Rating, from 70 to 73.
Can You Really Time The Stock Market?
This exclusive rating from Investor's Business Daily identifies share price performance with a 1 (worst) to 99 (best) score. The score shows how a stock's price behavior over the trailing 52 weeks holds up against all the other stocks in our database.
History shows that the best-performing stocks tend to have an RS Rating of over 80 as they begin their largest price moves. See if Galapagos ADR can continue to show renewed price strength and clear that threshold.
Galapagos ADR is not currently near a potential buying area. See if the stock goes on to form a sound pattern that could launch a new move.
Galapagos ADR reported 0% earnings growth in the latest quarterly report. Revenue increased 20%. The company is expected to report its latest earnings and sales numbers on or around Jul. 23.
The company earns the No. 114 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, TG Therapeutics and Inhibrx Biosciences are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
